Umpqua Bank Purchases 147 Shares of Stryker Co. (NYSE:SYK)

Umpqua Bank grew its position in shares of Stryker Co. (NYSE:SYK) by 2.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,516 shares of the medical technology company’s stock after buying an additional 147 shares during the quarter. Umpqua Bank’s holdings in Stryker were worth $2,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. American Century Companies Inc. raised its holdings in Stryker by 11.4% during the fourth quarter. American Century Companies Inc. now owns 743,693 shares of the medical technology company’s stock valued at $267,767,000 after acquiring an additional 75,897 shares during the period. Plancorp LLC grew its position in Stryker by 27.9% in the fourth quarter. Plancorp LLC now owns 941 shares of the medical technology company’s stock worth $339,000 after acquiring an additional 205 shares in the last quarter. Vestor Capital LLC grew its position in Stryker by 1,344.4% in the fourth quarter. Vestor Capital LLC now owns 16,755 shares of the medical technology company’s stock worth $6,033,000 after acquiring an additional 15,595 shares in the last quarter. Mizuho Securities USA LLC boosted its position in shares of Stryker by 46.3% during the fourth quarter. Mizuho Securities USA LLC now owns 32,518 shares of the medical technology company’s stock valued at $11,708,000 after buying an additional 10,286 shares during the period. Finally, Cyrus J. Lawrence LLC boosted its position in shares of Stryker by 1.1% during the fourth quarter. Cyrus J. Lawrence LLC now owns 23,931 shares of the medical technology company’s stock valued at $8,616,000 after buying an additional 269 shares during the period. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a report on Tuesday, March 4th. Needham & Company LLC reissued a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Truist Financial upped their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Stock Down 0.8 %

SYK stock opened at $371.38 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm’s 50-day simple moving average is $384.28 and its 200 day simple moving average is $373.93. The stock has a market cap of $141.71 billion, a PE ratio of 47.86, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business posted $3.46 EPS. As a group, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.